دورية أكاديمية
Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland
| العنوان: | Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland |
|---|---|
| المؤلفون: | Dominika Krupa, Marcin Czech, Ewa Chudzyńska, Beata Koń, Anna Kostera-Pruszczyk |
| المصدر: | Healthcare, Vol 11, Iss 10, p 1515 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | spinal muscular atrophy, real-world evidence, nusinersen, therapy costs, budget impact, Medicine |
| الوصف: | Background: Spinal muscular atrophy (SMA) is a debilitating neuromuscular disease resulting in children’s mortality and disability. Nusinersen is available to all SMA patients in Poland since 2019. Aim: To compare mortality or disease progression to mechanical ventilation in two patient cohorts before and after the program’s introduction. Additionally, to describe the patient population treated with nusinersen and costs incurred by the public payer. Methods: We used the National Health Fund (NHF) database to identify patients born in either 2014 or 2019, who received at least two health services with an ICD10 G12 diagnosis. Outcomes were time to event: death or first mechanical ventilation. We identified all benefits received by nusinersen-treated patients, between 1 January 2019 and 31 May 2022. Results: Children with SMA born in 2019 had significantly lower mortality in the first years of their lives than children born in 2014. Approximately 875 patients (all age groups) were treated with nusinersen in the analysis period. The cost of causal drugs in this period amounted to €51.4 million. The cost of healthcare benefits amounted to €14.9 million. Conclusions: The drug program to treat SMA improved patient care in Poland. The NHF database was a reliable source to monitor resource-intensive therapies’ costs, demography, and selected patient outcomes. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2227-9032 |
| العلاقة: | https://www.mdpi.com/2227-9032/11/10/1515Test; https://doaj.org/toc/2227-9032Test |
| DOI: | 10.3390/healthcare11101515 |
| الوصول الحر: | https://doaj.org/article/6966662795aa4d848ce8436aa8a4f220Test |
| رقم الانضمام: | edsdoj.6966662795aa4d848ce8436aa8a4f220 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.6966662795aa4d848ce8436aa8a4f220 969 3 Academic Journal academicJournal 969.100524902344 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.6966662795aa4d848ce8436aa8a4f220&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/6966662795aa4d848ce8436aa8a4f220 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=22279032&ISBN=&volume=11&issue=10&date=20230501&spage=1515&pages=1515-1515&title=Healthcare&atitle=Real%20World%20Evidence%20on%20the%20Effectiveness%20of%20Nusinersen%20within%20the%20National%20Program%20to%20Treat%20Spinal%20Muscular%20Atrophy%20in%20Poland&id=DOI:10.3390/healthcare11101515 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Dominika+Krupa%22">Dominika Krupa</searchLink><br /><searchLink fieldCode="AR" term="%22Marcin+Czech%22">Marcin Czech</searchLink><br /><searchLink fieldCode="AR" term="%22Ewa+Chudzyńska%22">Ewa Chudzyńska</searchLink><br /><searchLink fieldCode="AR" term="%22Beata+Koń%22">Beata Koń</searchLink><br /><searchLink fieldCode="AR" term="%22Anna+Kostera-Pruszczyk%22">Anna Kostera-Pruszczyk</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Healthcare, Vol 11, Iss 10, p 1515 (2023) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => MDPI AG, 2023. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Medicine ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22spinal+muscular+atrophy%22">spinal muscular atrophy</searchLink><br /><searchLink fieldCode="DE" term="%22real-world+evidence%22">real-world evidence</searchLink><br /><searchLink fieldCode="DE" term="%22nusinersen%22">nusinersen</searchLink><br /><searchLink fieldCode="DE" term="%22therapy+costs%22">therapy costs</searchLink><br /><searchLink fieldCode="DE" term="%22budget+impact%22">budget impact</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: Spinal muscular atrophy (SMA) is a debilitating neuromuscular disease resulting in children’s mortality and disability. Nusinersen is available to all SMA patients in Poland since 2019. Aim: To compare mortality or disease progression to mechanical ventilation in two patient cohorts before and after the program’s introduction. Additionally, to describe the patient population treated with nusinersen and costs incurred by the public payer. Methods: We used the National Health Fund (NHF) database to identify patients born in either 2014 or 2019, who received at least two health services with an ICD10 G12 diagnosis. Outcomes were time to event: death or first mechanical ventilation. We identified all benefits received by nusinersen-treated patients, between 1 January 2019 and 31 May 2022. Results: Children with SMA born in 2019 had significantly lower mortality in the first years of their lives than children born in 2014. Approximately 875 patients (all age groups) were treated with nusinersen in the analysis period. The cost of causal drugs in this period amounted to €51.4 million. The cost of healthcare benefits amounted to €14.9 million. Conclusions: The drug program to treat SMA improved patient care in Poland. The NHF database was a reliable source to monitor resource-intensive therapies’ costs, demography, and selected patient outcomes. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2227-9032 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.mdpi.com/2227-9032/11/10/1515; https://doaj.org/toc/2227-9032 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3390/healthcare11101515 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/6966662795aa4d848ce8436aa8a4f220" linkWindow="_blank">https://doaj.org/article/6966662795aa4d848ce8436aa8a4f220</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.6966662795aa4d848ce8436aa8a4f220 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/healthcare11101515
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 1515
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => spinal muscular atrophy
[Type] => general
)
[1] => Array
(
[SubjectFull] => real-world evidence
[Type] => general
)
[2] => Array
(
[SubjectFull] => nusinersen
[Type] => general
)
[3] => Array
(
[SubjectFull] => therapy costs
[Type] => general
)
[4] => Array
(
[SubjectFull] => budget impact
[Type] => general
)
[5] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Real World Evidence on the Effectiveness of Nusinersen within the National Program to Treat Spinal Muscular Atrophy in Poland
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dominika Krupa
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marcin Czech
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ewa Chudzyńska
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Beata Koń
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Anna Kostera-Pruszczyk
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 05
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 22279032
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 11
)
[1] => Array
(
[Type] => issue
[Value] => 10
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Healthcare
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |